TickerTalks
Browse all tickers →
TickerTalks›$AZN
AZAZN

AstraZeneca PLC

$AZN·$266B·Drug Manufacturers - General·Healthcare
$169.29+0.5%YTD-11.1%1Y+19.2%
Mentions · last 7 days
2026-07-10: 171 posts2026-07-11: 51 posts2026-07-12: 100 posts2026-07-13: 163 posts2026-07-14: 67 posts2026-07-15: 33 posts2026-07-16: 13 posts617+9%
Price updated 7m ago·X counts updated 15h ago
AZAZN
$AZNAstraZeneca PLC
$169.29+0.55%617 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AZN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersCooling offAI verdict · as of 2026-07-16

Catching its breath after a run — could pick back up or fade from here.

Trillion-market-cap pharma just lost $27B on a big trial fail — oncology engine still running.

AstraZeneca is one of the largest UK-based pharmaceutical companies — oncology, cardiovascular, and rare disease franchises anchoring a global product portfolio. The stock just fell 6% and lost roughly $27B in market cap when Wainua (eplontersen) failed its Phase 3 CARDIO-TTRansform trial in ATTR-CM.

  • Revenue grew 13% YoY to $14B last quarter with a 28% operating margin — the underlying oncology and cardiovascular engines are running, even with the Wainua setback pulling one specific asset off the timeline.
  • Trades at 27x TTM earnings and 4.7x sales — reasonable for a diversified global pharma with 22% ROIC, and the Wainua failure isolated to a single indication doesn't structurally break the franchise multiple.
  • The Dizal in-licensing deal for the lung-cancer drug (announced July 15) is exactly the kind of pipeline-refresh a mega-cap pharma does when a lead trial disappoints — capital reallocation is the expected response.
  • Two law-firm investigation notices (Pomerantz, Levi & Korsinsky) landed July 14 — opportunistic post-drawdown activity, and typical rather than a specific claim signal.
  • 52-week position 41st percentile after the Wainua drop — the tape has priced the trial failure; the ABVX-bid and SGMO-gene-therapy speculation in the corpus is the tape trying to imagine what AstraZeneca does next with the freed capital.

July 27 Q2 earnings is where the response to the Wainua setback gets validated: revenue growth held above 10% plus a clear pipeline-reallocation narrative is what turns cooling into a base; a Q3 guide reflecting a broader oncology slowdown is where the -11% YTD extends further. Real diversified pharma with a real recent setback — the multiple has already priced the news; execution now decides direction.

Agrees with X sentimentThe bearish X read on the Wainua failure is factually right — $27B in market cap and a real trial disappointment. Where the crowd's speculation about an ABVX bid or SGMO pivot is analytically fair: when a lead asset fails, capital reallocation follows, and that's the story the tape is now trading.

What to watch: July 27 Q2 earnings — need revenue growth held above 10% and a clear pipeline-reallocation narrative. A Q3 guide reflecting broader oncology slowdown is where -11% YTD extends further.

On the calendar: 2026-07-27 — Q2 earnings

beta missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment26 posts analyzed · as of 2026-07-15

AstraZeneca chatter is dominated by a major clinical setback: the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen) added to standard of care in ATTR-CM failed to meet its primary efficacy endpoint. AZN fell -6% (and IONS -17-24%), with AZN losing about $27B in market value in one session. Bulls try to salvage the picture by speculating AZN could pivot capital toward an ABVX bid (obesity) or SGMO gene-therapy (Fabry), but the immediate read across the tape is negative. BBIO was the direct beneficiary (+15-16% on lower ATTR-CM competition). Community sentiment on AZN itself has visibly cooled.

Read the AI verdict + X sentiment for $AZN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AZN.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $AZN

Neutral — Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios; the oral GLP-1 and obesity pipeline expansion and competition does not materially affect this business's near-term earnings.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+17.8%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
27.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
12.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$2.58$2.57+0.4%
Q4 2025Feb 10, 2026$2.12$2.18-2.8%
Q3 2025Nov 6, 2025$2.38$2.29+3.9%
Q2 2025Jul 29, 2025$2.18$2.16+0.9%
Next earningsMon, Jul 27·consensus EPS $2.50

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.3B+12.5%82.5%27.8%$1.99$1.8B
Q4 FY25$15.5B+4.1%79.9%19.2%$1.51$1.4B
Q3 FY25$15.2B+12.0%81.6%23.6%$1.63$4.4B
Q2 FY25$14.5B+11.7%82.9%24.3%$1.58$1.5B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$63.3B$61.7B – $64.9B$10.25$10.10 – $10.4917
FY27$67.7B$64.3B – $69.4B$11.59$11.24 – $11.8118
FY28$72.2B$71.9B – $72.4B$12.96$9.56 – $14.4121
FY29$77.5B$72.8B – $80.1B$15.03$13.85 – $15.6810
FY30$82.9B$77.9B – $85.7B$16.88$15.55 – $17.6110

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.42%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 770.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 20Mani SharmaSee Remarks11.9K sh$2.2M
+ 4 other (4 awards) in window

See when $AZN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 193
SC 13D/AActivist amendmentFeb 6SC 13D/A
+ 70 other (55 6-Ks · 3 CERTs · 3 8-A12Bs · 2 25-NSEs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinskyprnewswire.com·1d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZNprnewswire.com·1d agoAZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drugzacks.com·2d agoAstraZeneca's Oncology Engine Keeps Running Despite Wainua Setbackseekingalpha.com·2d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZNglobenewswire.com·3d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$GILD$OGN
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport